- Home
- ASMB vs ORMP Comparison
ASMB vs ORMP Comparison
Compare ASMB & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- ORMP
- Stock Information
- Founded
- ASMB 2005
- ORMP 2002
- Country
- ASMB United States
- ORMP United States
- Employees
- ASMB 73
- ORMP N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- ORMP Health Care
- Exchange
- ASMB Nasdaq
- ORMP Nasdaq
- Market Cap
- ASMB 138.4M
- ORMP N/A
- IPO Year
- ASMB 2010
- ORMP N/A
- Fundamental
- Price
- ASMB $18.56
- ORMP $2.16
- Analyst Decision
- ASMB Strong Buy
- ORMP Hold
- Analyst Count
- ASMB 3
- ORMP 1
- Target Price
- ASMB $33.00
- ORMP N/A
- AVG Volume (30 Days)
- ASMB 41.7K
- ORMP 77.2K
- Earning Date
- ASMB 08-07-2025
- ORMP 08-15-2025
- Dividend Yield
- ASMB N/A
- ORMP N/A
- EPS Growth
- ASMB N/A
- ORMP N/A
- EPS
- ASMB N/A
- ORMP N/A
- Revenue
- ASMB $32,154,000.00
- ORMP $2,000,000.00
- Revenue This Year
- ASMB $0.04
- ORMP N/A
- Revenue Next Year
- ASMB N/A
- ORMP N/A
- P/E Ratio
- ASMB N/A
- ORMP N/A
- Revenue Growth
- ASMB 148.33
- ORMP 196.74
- 52 Week Low
- ASMB $7.75
- ORMP $1.82
- 52 Week High
- ASMB $19.93
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- ASMB 70.84
- ORMP 48.10
- Support Level
- ASMB $17.76
- ORMP $2.10
- Resistance Level
- ASMB $18.92
- ORMP $2.25
- Average True Range (ATR)
- ASMB 0.84
- ORMP 0.08
- MACD
- ASMB -0.03
- ORMP 0.00
- Stochastic Oscillator
- ASMB 82.73
- ORMP 52.63
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.